Fibromuscular cap composition is important for the stability of established atherosclerotic plaques in mature WHHL rabbits treated with statins

被引:127
作者
Shiomi, M
Ito, T
Hirouchi, Y
Enomoto, M
机构
[1] Kobe Univ, Sch Med, Inst Expt Anim, Chuo Ku, Kobe, Hyogo 6500017, Japan
[2] Biosaefety Res Ctr Foods Drugs & Pesticides, Shizuoka, Japan
关键词
fibromuscular cap; atherosclerosis; pravastatin; fluvastatin; WHHL rabbit; vulnerable plaque;
D O I
10.1016/S0021-9150(00)00708-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We examined the relationship between plaque vulnerability and fibromuscular cap composition using hydrophilic pravastatin and lipophilic fluvastatin. WHHL rabbits aged 10 months were given pravastatin (50 mg/kg) or fluvastatin (20 mg/kg) for 52 weeks. The atherosclerotic lesions were immunohistochemically or conventionally stained and the components were analyzed with a color image analyzer. Compared with the control group, the plasma cholesterol levels were decreased by about 25% in both statin groups. Pravastatin decreased the lipid components (macrophages + extracellular lipids) in whole aortic plaques by 34% and the fibrous caps of coronary plaques by 55%. Fluvastatin decreased the fibromuscular components (smooth muscle cells + collagen fibers) in whole aortic plaques and in the fibromuscular caps of the aortic and coronary plaques. In the pravastatin group, the vulnerability index, the ratio of (lipid components)/(fibromuscular components), was decreased in whole aortic plaques by 28% and in the fibromuscular caps of coronary lesions by 61%, while the indexes were increased in the fluvastatin group. The incidence of vulnerable plaques was decreased by 74% in the coronary plaques of the pravastatin group. Our results suggest that the stability of atheromatous plaques was improved due to a decrease of the lipid components and vulnerability index of the fibromuscular cap by pravastatin. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:75 / 84
页数:10
相关论文
共 39 条
[1]   Dietary lipid lowering reduces tissue factor expression in rabbit atheroma [J].
Aikawa, M ;
Voglic, SJ ;
Sugiyama, S ;
Rabkin, E ;
Taubman, MB ;
Fallon, JT ;
Libby, P .
CIRCULATION, 1999, 100 (11) :1215-1222
[2]   Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma - A potential mechanism of lesion stabilization [J].
Aikawa, M ;
Rabkin, E ;
Okada, Y ;
Voglic, SJ ;
Clinton, SK ;
Brinckerhoff, CE ;
Sukhova, GK ;
Libby, P .
CIRCULATION, 1998, 97 (24) :2433-2444
[3]  
AIKAWA M, IN PRESS CIRCULATION
[4]   CYTOKINES AND GROWTH-FACTORS POSITIVELY AND NEGATIVELY REGULATE INTERSTITIAL COLLAGEN GENE-EXPRESSION IN HUMAN VASCULAR SMOOTH-MUSCLE CELLS [J].
AMENTO, EP ;
EHSANI, N ;
PALMER, H ;
LIBBY, P .
ARTERIOSCLEROSIS AND THROMBOSIS, 1991, 11 (05) :1223-1230
[5]   The interaction of diltiazem with lovastatin and pravastatin [J].
Azie, NE ;
Brater, DC ;
Becker, PA ;
Jones, DR ;
Hall, SD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (04) :369-377
[6]   Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy [J].
Ballantyne, CM ;
Herd, JA ;
Ferlic, LL ;
Dunn, JK ;
Farmer, JA ;
Jones, PH ;
Schein, JR ;
Gotto, AM .
CIRCULATION, 1999, 99 (06) :736-743
[7]   Pro-apoptotic effect of fluvastatin on human smooth muscle cells [J].
Buemi, M ;
Allegra, A ;
Senatore, M ;
Marino, D ;
Medici, MA ;
Aloisi, C ;
Di Pasquale, G ;
Corica, F .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 370 (02) :201-203
[8]   Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228) on migration, proliferation and cholesterol synthesis in arterial myocytes [J].
Corsini, A ;
Arnaboldi, L ;
Raiteri, M ;
Quarato, P ;
Faggiotto, A ;
Paoletti, R ;
Fumagalli, R .
PHARMACOLOGICAL RESEARCH, 1996, 33 (01) :55-61
[9]  
DAVIES MJ, 1993, BRIT HEART J, V69, P377
[10]   Stability and instability: Two faces of coronary atherosclerosis - The Paul Dudley White Lecture 1995 [J].
Davies, MJ .
CIRCULATION, 1996, 94 (08) :2013-2020